Genetically Engineered Oils

Among patients with psoriasis, approximately 50% are women and almost 75 % of them are under the age of 40 years. Thus, most women with psoriasis have childbearing potential. When pregnancy occurs in 22 % of patients, the activity of psoriasis persists, characteristic of the course before pregnancy, in 23 % of women, the course of the disease worsens. The article provides up-to-date data on the management of pregnant patients with psoriasis. To improve pregnancy outcomes in patients with psoriasis, it is important to prevent exacerbation of the disease. The choice of drug therapy in this case is based on an assessment of the ratio of the risk of undesirable effects of the drugs on the developing fetus and the risk of the development of exacerbation of psoriasis, which can cause an adverse pregnancy outcome. Despite the fact that the available clinical experience of using genetically engineered drugs is still limited, with a certain degree of confidence we can say that there is no increase in the risk of adverse pregnancy outcomes associated with therapy with certolizumab pegol.

Download Full-text

Quantum Dot Bioconjugates as Energy Donors in Fluorescence Resonance Energy Transfer Assays

MRS Proceedings ◽

10.1557/proc-773-n7.9 ◽

2003 ◽

Vol 773 ◽

Author(s):

Aaron R. Clapp ◽

Igor L. Medintz ◽

J. Matthew Mauro ◽

Hedi Mattoussi

Keyword(s):

Energy Transfer ◽

Quantum Dot ◽

Organic Dyes ◽

Resonance Energy Transfer ◽

Resonance Energy ◽

Genetically Engineered ◽

Molar Ratio ◽

Binding Assays ◽

Specific Sequence ◽

Donor Acceptor

AbstractLuminescent CdSe-ZnS core-shell quantum dot (QD) bioconjugates were used as energy donors in fluorescent resonance energy transfer (FRET) binding assays. The QDs were coated with saturating amounts of genetically engineered maltose binding protein (MBP) using a noncovalent immobilization process, and Cy3 organic dyes covalently attached at a specific sequence to MBP were used as energy acceptor molecules. Energy transfer efficiency was measured as a function of the MBP-Cy3/QD molar ratio for two different donor fluorescence emissions (different QD core sizes). Apparent donor-acceptor distances were determined from these FRET studies, and the measured distances are consistent with QD-protein conjugate dimensions previously determined from structural studies.

Download Full-text

Environmental effects of insect resistant genetically-engineered crops and implications for regulation

10.1603/ice.2016.93255 ◽

2016 ◽

Author(s):

Jörg Romeis

Keyword(s):

Environmental Effects ◽

Genetically Engineered ◽

Genetically Engineered Crops ◽

Insect Resistant

Download Full-text

SELECTION AND SWITCHING OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN TREATMENT OF JUVENILE ARTHRITIS

PEDIATRIA Journal named after G N SPERANSKY ◽

10.24110/0031-403x-2018-97-3-52-61 ◽

2018 ◽

Vol 97 (3) ◽

pp. 52-61

Author(s):

E.S. Zholobova ◽

◽

A.K. Ignatova ◽

N.G. Seylanova ◽

A.P. Golubeva ◽

...

Keyword(s):

Biological Agents ◽

Genetically Engineered ◽

Juvenile Arthritis

Download Full-text

Olfactomedin-like 2A, 2B and 3 are differentially expressed in breast cancer metastases.

10.31219/osf.io/7g34z ◽

2019 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Genetically Engineered ◽

Differentially Expressed ◽

Genetically Engineered Mouse Models ◽

Breast Cancer Metastases ◽

Multiple Datasets ◽

Cancer Metastases ◽

Distant Organ ◽

Metastatic Process ◽

Differential Gene

Differential gene expression analysis of multiple datasets, in mice and in men revealed that transcripts of the olfactomedin-like family are differentially expressed in metastases, both in patients with breast cancer and in genetically engineered mouse models of breast cancer. The expression of olfactomedin-like genes was perturbed in metastases to the bone, brain and the lung, suggesting that these molecules function in the metastatic process rather than having tissue-specific associations with the site of dissemination. The olfactomedin-like family may play a role in the progression of breast cancer from frank tumor to colonization of distant organ sites.

Download Full-text

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Case Medical Research ◽

10.31525/ct1-nct04135092 ◽

2019 ◽

Author(s):

Keyword(s):

T Cells ◽

T Cell ◽

Phase Ii ◽

T Cell Receptors ◽

Phase Ii Study ◽

Metastatic Cancer ◽

Genetically Engineered ◽

Single Patient ◽

Cell Receptors

Download Full-text

Pharmacoeconomic analysis of using genetically engineered biologic drugs for treating adult patients with moderate to severe plaque psoriasis in the Russian Federation

10.33920/med-13-2001-06 ◽

2020 ◽

pp. 57-65

Author(s):

Maksim Frolov ◽

Vladimir Rogov ◽

Alla Salasyuk

Keyword(s):

Plaque Psoriasis ◽

Impact Analysis ◽

Pharmacoeconomic Analysis ◽

Certolizumab Pegol ◽

Genetically Engineered ◽

Adult Patients ◽

Comparable Efficacy ◽

Biologic Drugs ◽

Severe Plaque Psoriasis ◽

Cost Minimisation Analysis

The aim of the study was to assess clinical and economic effectiveness of netakimab compared to other genetically engineered biologic drugs (infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, certolizumab pegol) for the treatment of adult patients with moderate to severe plaque psoriasis. We have conducted cost-benefit analysis, cost-minimisation analysis, and budget impact analysis. We have considered only direct medical costs. The results of the study show that netakimab has higher or comparable efficacy and significantly lower costs compared to other biologic drugs, that makes it the most preferable treatment option for patients with moderate to severe plaque psoriasis. Use of netakimab in clinical practice will significantly reduce budget expenditures and increase patient access to biologic therapy.

Download Full-text